title: The effect of Asarinin on Toll-like pathway in rats after cardiac allograft implantation.
abstract: OBJECTIVE
  The objective of this study was to study the mechanism of the anti-rejection effect of Asarinin in rats that underwent cardiac allograft implantation.
  
  
  METHODS
  Hearts from Wistar rats were transplanted into the abdominal cavity of Sprague Dawley rats (SD rats) 64 SD rats received either cyclosporin A (CsA), Asarinin, or demi-dose of cyclosporine A and Asarinin through oral administration. On the seventh day post-transplantation, the expression of Toll-like receptor 4 (TLR4), chemokine (C-X-C motif) receptor 3 (CXCR3) in myocardium, and the level of interleukin (IL)-12 in the peripheral blood were analyzed 7 days after transplantation.
  
  
  RESULTS
  The survival time in 3 groups (CsA group, Asarinin group, and semi-dose CsA group) prolonged (P < .01), the microscope myocardial histopathology in 3 groups (CsA group, Asarinin group and semi-dose CsA group) relieved, the expression of TLR4 and CXCR3 in 3 groups was significantly decreased (P < .01) when compared with the control group. The level of IL-12 decreased remarkably (P < .05) in the 3 groups when compared with the control group.
  
  
  CONCLUSIONS
  The combined data suggested that Asarinin decreased peripheral blood concentration of IL-12 and inhibited the expression of TLR4 and CXCR3, which means Asarinin may have a role on TLR4 pathway and produced prolongation of allograft heart survival.
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: J
authors.initials: J
authors.lastname: Gu
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: Z
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: G
authors.initials: G
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: D
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China.
authors.forename: X
authors.initials: X
authors.lastname: Bai
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China. Electronic address: drlixueqi@163.com.
authors.forename: X
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Cardiology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People's Republic of China. Electronic address: drzhanglilii@163.com.
authors.forename: Z
authors.initials: Z
authors.lastname: Lili
mesh_terms: D064591:Allografts / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004149:Dioxoles / Q000627:therapeutic use*; D006084:Graft Rejection / Q000378:metabolism* / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects; D016027:Heart Transplantation; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018664:Interleukin-12 / Q000097:blood; D017705:Lignans / Q000627:therapeutic use*; D008297:Male; D023421:Models, Animal; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D054367:Receptors, CXCR3 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism*; D014184:Transplantation, Homologous
chemical_list: D000975:Antioxidants; D004149:Dioxoles; D007166:Immunosuppressive Agents; D017705:Lignans; D054367:Receptors, CXCR3; D051197:Toll-Like Receptor 4; D018664:Interleukin-12; D016572:Cyclosporine; C054125:sesamin